16 April 2020: Critical care diagnostics also termed as the point of care (POC) are the approved tests that offer quick result and are performed near the patient. Over the counter and self-testing also come under critical care diagnostics. Critical care diagnostics comprise of cardiac markers diagnostics, cancer biomarker test, blood glucose testing, blood gas and electrolyte analysis, pregnancy testing, drugs of abuse, food pathogens screening, urine stripe testing, cholesterol screening, infectious disease testing, and hemoglobin diagnostics.
Immunoproteins Segment Contribute Dominant Share in the End User Segment
The major application variants of the critical care diagnostics market include flow cytometry, routine and special chemistry, hematology, microbial and infectious diseases, coagulation, immunoproteins, and others.
The immunoproteins sector accounted for the largest share in the market and is anticipated to expand at the fastest CAGR in the forthcoming period. The factors that attributed to the growth include an increase in the demand for accurate and rapid diagnosis and the ability to decrease the recovery time of patients.
In addition, increasing availability, growing patient population base, and consciousness about infectious disease POC testing products are the key factors contributing to the sector’s development in the forecast period. As the consciousness levels of patients for improved healthcare selections have enhanced and physician’s data of target therapy has improved, the demand for these diagnostics has extended.
The growth of the global market is mainly driven by factors, such as flow cytometry tests, coagulation tests, and clinical chemistry among others. Furthermore, microbiology and infectious tests with immunoproteins assays are anticipated to propel segment growth in the years to come.
Market Insights:
The key players are majorly involved in new product development, technological advancements, joint ventures, collaborations, and partnerships, to uphold their position in the industry. For instance, in February 2016, Abbott acquired healthcare management company i.e. Alere, which is offering the point-of-care solution.
For instance, the i-Stat blood gas analyzer by Abbott associated self-contained cartridges with microfluidic constituents and electrochemical detection, providing sensitive, and accurate results. Demand for cost-efficient, accurate, and rapid diagnostic tests, and increasing awareness are expected to initiate developments in the market. Leading players operating in the critical care diagnostics market are Alere, Inc.; Abbott.; Beckman-Coulter; Becton Dickinson & Co.; and Roche Diagnostics among others.
No comments:
Post a Comment